Intra-aortic balloon pump for treatment of refractory ventricular tachycardia in Tako-Tsubo cardiomyopathy: A case report

Elisabetta Lisi a,b, Valentina Guida a,b, Simonetta Blengino a, Elisabetta Pedrazzi a, Deborah Ossola a, Gianfranco Parati a,b,⁎

a Dept. of Cardiology, Istituto Auxologico Italiano, Milano, Italy
b Dept. of Health Sciences, University of Milano-Bicocca, Milano, Italy

ARTICLE INFO

Article history:
Received 28 January 2014
Accepted 14 March 2014
Available online 21 March 2014

Keywords:
Tako-tsubo cardiomyopathy
arrhythmias
intra-aortic balloon pump

Tako-Tsubo cardiomyopathy (TTC) is characterized by a transient dysfunction of the left ventricular apex, often triggered by emotional or physical stress. Estimated prevalence of TTC ranges from 0.1 to 2.2% of patients with acute coronary syndrome (ACS). It usually occurs in old postmenopausal women. It often presents with chest pain and ECG changes (ST elevation in precordial leads and subsequent T wave inversion) and minimal myocardial enzymatic elevation which could mimic ACS, but in absence of coronary artery disease. Typical echocardiographic pattern shows apical-mid-ventricular akinesis and basal hyperkinesis. Acute heart failure and cardiogenic shock mimic ACS, but in absence of coronary artery disease. Typical TTC complications, but ventricular arrhythmias (VA) may also occur [1].

We report a case of TTC presenting as an incessant sustained ventricular tachycardia (VT).

A 81-year-old woman was brought to our emergency department with shortness of breath and chest pain. She had a history of hypertension under therapy with valsartan, amiodipine and clonidine, diabetes and hypercholesterolemia treated respectively with metformin and rosuvastatin. One year before, paradoxical atrial fibrillation occurred and amiodarone prophylaxis were introduced. On physical examination in emergency department the patient was conscious, with heart rate 110 beats/min and blood pressure 120/70 mm Hg. The electrocardiogram showed a wide-QRS tachycardia with left bundle branch block morphology compatible with sustained monomorphic VT (Fig. 1).

On laboratory tests serum troponin I was 0.91 ng/mL, CKMB 9.1 ng/mL (normal values <0.01 ng/mL and <6.3 ng/mL, respectively) and potassium 3.5 mmol/L. The patient was initially treated with iv MgSO4 and potassium, since she was already under amiodarone therapy. Four ineffective electrical shocks were delivered.

In intensive care unit she was treated with iv lidocaine, diuretics, a non-catecholamine inotrope, such as levosimendan, might be effective in stabilizing patients with refractory VA after myocardial infarction by increasing coronary perfusion pressure, reducing transmyocardial wall stress and maintaining adequate systemic perfusion [9].

The day after, due to persistence of sustained VT, low dose metoprolol was added and lidocaine was reintroduced with no benefit. After few hours we observed a rapid worsening of hemodynamic status consistent with CS. Therefore, upon orotracheal intubation, intra-aortic balloon pump (IABP) was placed, with prompt interruption of VT and progressive improvement of hemodynamic conditions. 24 h later levosimendan was added to support IABP weaning off.

At continuous ECG monitoring no VA were recorded and echocardiogram showed a progressive resolution of left ventricular (LV) contractile abnormalities with LVEF 63%.

Some days later, ECG showed diffusely deep inverted T waves and QTc 500 ms, so amiodarone was stopped. The patient was discharged with warfarin, lysine-acetylsalicylate 75 mg, ramipril 5 mg bid, bisoprolol 2.5 mg od, rosuvastatin 5 mg od and amiodipine 5 mg od.

Life-threatening VA are occasionally described as a TTC clinical manifestation, reported in 3.4% of cases and in 1.1% of cases as its first clinical presentation [2,3]. In spite of underlying sympathetic activation and frequently associated QTc prolongation [5], VA seem to be less common than expected in TTC, although they might represent an important component of this syndrome. Indeed, QTc prolongation associated with autonomic dysregulation in TTC is recognized as important risk factor for VT [2]. As shown in Wittstein’s paper [4] in TTC patients plasma catecholamine levels are two-to-threefold increased as compared with ACS and LV failure patients. However the possible mechanisms underlying myocardial stunning in TTC are controversial and could include epicardial coronary spasm, microvascular dysfunction and direct catecholamine induced myocyte injury. As TTC typical contractile abnormalities are localized in multiple vascular territories, the epicardial spasm hypothesis seems unlikely; whereas both microvascular spasm, suggesting sympathetically mediated microcirculatory dysfunction, and direct myocyte injury, may be involved in myocardial stunning [4]. Microvascular dysfunction can lead to an oxygen demand impairment that could increase myocardial vulnerability and create the ideal substrate for VA. In Gianni’s metanalysis CS occurred in 4.2% of TTC patients and almost 10% of them needed IABP [5]; similarly in Sharkey’s paper about 30% of TTC patients with CS required inotropes or mechanical circulation support [6]. Catecholamine inotropes are often used in the treatment of CS. However, since catecholamine surge seems to be implicated in TTC pathogenesis, inotrope use is controversial. As described in isolated case-reports, only a non-catecholamine inotrope, such as levosimendan, might be beneficial in TTC patients with CS [7].

In this clinical context even the use of IABP support is still debated. Thanks to its property to improve myocardial perfusion and reduce afterload and myocardial oxygen consumption, IABP can be used in patients with CS after myocardial infarction. Albeit latest international ST elevation myocardial infarction (STEMI) guidelines [8] downgrade IABP use in CS after STEMI from class I to class II, IABP seems to be effective in stabilizing patients with refractory VA after myocardial infarction by increasing coronary perfusion pressure, reducing transmyocardial wall stress and maintaining adequate systemic perfusion [9].

On the contrary, there are only few reports about IABP use in CS patients with normal coronary arteries [10] and even less is available about its use in TTC, especially when CS caused by VA occurs. In our case for the first time we described a successful IABP use in a TTC patient.

⁎ Corresponding author at: Dept. of Cardiology, S.Luca Hospital, Istituto Auxologico Italiano & University of Milan-Bicocca, Piazza Brescia 20, Milan, 20149-Italy. Tel.: +39 0261912949; fax: +39 02619112956.
E-mail address: gianfranco.parati@unimib.it (G. Parati).
with hemodynamic instability due to VT refractory to conventional antiarrhythmic therapy. After IABP application, we observed a quick resolution of VA, followed by a progressive LV function improvement.

In conclusion, VT can be more frequent than expected life-threatening presentation of TTC. There is no clear evidence about its best treatment in TTC patients, especially when conventional antiarrhythmic procedures failed. In particular, while IABP has been reported to effectively manage refractory VT in ischemic patients, no evidence is available on its usefulness in non-ischemic refractory VT. Our case report suggests that IABP may be considered as support treatment in refractory non-ischemic VT, especially when hemodynamic impairment occurs. Our observation should thus stimulate additional studies aimed to systematically test this possible therapeutic approach.

References


http://dx.doi.org/10.1016/j.ijcard.2014.03.102
0167-5273/© 2014 Published by Elsevier Ireland Ltd.